MedTrace Logo

NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma

NCT07680699 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-07-02

No results posted yet for this study

Summary

This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.

Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.

The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice.

No treatments are assigned as part of the study.

Conditions

Interventions

OTHER

Anti-PD1 Therapy Timing

This is an observational study variable. The timing of anti-PD1 therapy initiation in relation to surgery is determined by the treating physician as part of routine clinical practice. The study does not assign or modify any treatment.

Sponsors & Collaborators

  • AC Camargo Cancer Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-23
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680699 on ClinicalTrials.gov